{"gene":"ZBTB10","run_date":"2026-04-28T23:00:23","timeline":{"discoveries":[{"year":2010,"finding":"ZBTB10 functions as a transcriptional repressor of specificity protein (Sp) transcription factors Sp1, Sp3, and Sp4; its expression is suppressed by miR-27a, and induction of ROS downregulates miR-27a, thereby inducing ZBTB10 and repressing Sp-regulated genes (cyclin D1, c-Met, EGFR, bcl-2, survivin, VEGF/VEGFRs) in colon cancer cells.","method":"RNA interference, expression plasmid transfection, miR-27a modulation, RT-PCR, Western blot in RKO and SW480 colon cancer cells","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (RNAi, overexpression, antioxidant rescue), replicated across multiple papers","pmids":["21156786"],"is_preprint":false},{"year":2012,"finding":"Overexpression of ZBTB10 recapitulates Sp1/Sp3/Sp4 downregulation and reduces VEGF, survivin, and other Sp-regulated gene expression in breast cancer cells, confirming its role as an Sp repressor; miR-27a constitutively suppresses ZBTB10 expression, and betulinic acid disrupts this axis via cannabinoid receptor CB1/CB2-dependent signaling.","method":"ZBTB10 expression plasmid transfection, miR-27a mimic/inhibitor transfection, siRNA knockdown, Western blot, RT-PCR in MDA-MB-231 and BT474/MDA-MB-453 cells; xenograft mouse model","journal":"Molecular carcinogenesis; Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods across two independent studies, including in vivo validation","pmids":["22407812","22553354"],"is_preprint":false},{"year":2012,"finding":"miR-27a directly suppresses ZBTB10 expression; downregulation of miR-27a by follicle stimulating hormone leads to decreased ZBTB10, increased Sp1 activity, and upregulation of VEGF, Cox2, and survivin in ovarian cancer cells; antisense miR-27a or ZBTB10 overexpression blocks this FSH-induced response.","method":"Antisense miR-27a transfection, ZBTB10 overexpression, Sp1 siRNA knockdown, Western blot, RT-PCR in ovarian cancer cells","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods but single laboratory study","pmids":["23254909"],"is_preprint":false},{"year":2013,"finding":"ROS-mediated disruption of the miR-27a:ZBTB10 axis by curcuminoids induces ZBTB10, represses Sp1/Sp3/Sp4, and downregulates MDR1, demonstrating that Sp1/Sp3 regulate MDR1 expression downstream of ZBTB10 in colon cancer cells.","method":"RT-PCR, transfection with ZBTB10 expression construct and RNAi, Western blot in SW-480 and HT-29 colon cancer cells","journal":"Molecular nutrition & food research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods but single laboratory","pmids":["23471840"],"is_preprint":false},{"year":2019,"finding":"ZBTB10 is the first identified TTGGGG variant telomeric repeat-binding protein; its two C2H2 zinc fingers bind TTGGGG with nanomolar affinity, and its N-terminal region interacts with TRF2/RAP1; ZBTB10 co-localizes with a subset of telomeres in ALT-positive U2OS cells.","method":"DNA binding assays, pull-down, co-immunoprecipitation, fluorescence microscopy (co-localization), quantitative mass spectrometry","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding assay with affinity measurement, protein interaction by Co-IP, and localization by imaging, orthogonal methods in one study","pmids":["30629181"],"is_preprint":false},{"year":2021,"finding":"ZBTB10 is required for NF-κB activation in conventional dendritic cells (cDC1); ZBTB10 knockdown increases NKRF (NF-κB repressing factor) expression, abrogates p65 and RelB nuclear translocation, and suppresses co-stimulatory molecules (CD80, CD86) and cytokines (IL-12, IL-6, IL-10), impairing Th1 T cell differentiation.","method":"Zbtb10 shRNA knockdown in Mutu-DC cDC1 line, global transcriptome analysis, Western blot for p65/RelB nuclear translocation, T cell co-culture assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — clean KD with specific cellular and molecular phenotypic readouts, transcriptome validation, single laboratory","pmids":["33527393"],"is_preprint":false},{"year":2022,"finding":"ZBTB10 directly transcriptionally represses PKLR (pyruvate kinase L/R); loss of ZBTB10 in androgen-deprivation therapy-resistant prostate cancer activates PKLR, enhancing glycolysis and neuroendocrine differentiation.","method":"Loss-of-function studies, gene expression analysis, direct transcriptional regulation assays in prostate cancer cell lines","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — direct transcriptional regulation demonstrated with loss-of-function, single laboratory","pmids":["35306527"],"is_preprint":false},{"year":2022,"finding":"ZBTB10 is a direct target of miR-361-5p; overexpression of ZBTB10 reverses the pro-proliferative and anti-apoptotic effects of miR-361-5p in rheumatoid arthritis fibroblast-like synoviocytes, establishing a miR-361-5p/ZBTB10 regulatory axis in these cells.","method":"Dual luciferase reporter assay, rescue/overexpression experiments, CCK-8, flow cytometry, Western blot in RA-FLS cells","journal":"Autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 — direct target validation by luciferase assay plus rescue experiments, single laboratory","pmids":["35608340"],"is_preprint":false},{"year":2023,"finding":"Crystal structure of human ZBTB10 ZF1-2 in complex with double-stranded TTGGGG DNA revealed the molecular basis of variant telomeric repeat recognition; key residues were identified by calorimetric analysis and mutagenesis; a single amino acid mutant (Arg767Gln) shifts specificity toward TTAGGG.","method":"X-ray crystallography, isothermal titration calorimetry, site-directed mutagenesis, co-crystal structure of mutant with TTAGGG","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with calorimetric validation and mutagenesis in a single rigorous study","pmids":["36657642"],"is_preprint":false},{"year":2023,"finding":"ZBTB10 directly binds the HK1 promoter and activates HK1 transcription; in intermittent hypoxia, ZBTB10 is upregulated and drives HK1-dependent glycolysis in laryngeal cancer cells.","method":"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), ZBTB10 knockdown and overexpression, HK1 shRNA in laryngeal cancer and 293T cells","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and luciferase assays provide direct evidence of promoter binding and transcriptional activation, single laboratory","pmids":["37834257"],"is_preprint":false},{"year":2025,"finding":"ZBTB10 directly binds the ARRDC3 promoter to enhance ARRDC3 expression; elevated ARRDC3 interacts with β-4 integrin (ITGB4) and promotes its ubiquitination and degradation, leading to reduced PI3K/AKT phosphorylation and suppression of gastric cancer progression.","method":"Chromatin immunoprecipitation, co-immunoprecipitation, luciferase reporter assay, RNA-sequencing, phospho-proteomic profiling, ZBTB10 overexpression in vitro and xenograft models","journal":"Cellular oncology (Dordrecht, Netherlands)","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP for direct promoter binding, Co-IP for ARRDC3-ITGB4 interaction, phosphoproteomics, and in vivo validation; multiple orthogonal methods in one study","pmids":["39873948"],"is_preprint":false}],"current_model":"ZBTB10 is a BTB-ZF transcription factor that acts as a repressor of Sp1/Sp3/Sp4 transcription factors (itself suppressed post-transcriptionally by miR-27a and miR-361-5p), directly binds variant telomeric TTGGGG repeats via its C2H2 zinc fingers and interacts with TRF2/RAP1 at ALT telomeres, transcriptionally activates or represses target genes (including ARRDC3, HK1, and PKLR) through direct promoter binding, and modulates NF-κB signaling in dendritic cells, collectively regulating cancer cell proliferation, metabolism, and immune activation."},"narrative":{"teleology":[{"year":2010,"claim":"Establishing ZBTB10 as the missing Sp transcription factor repressor resolved how ROS and miR-27a converge to control Sp-dependent oncogene programs.","evidence":"miR-27a modulation, ZBTB10 overexpression/RNAi, and antioxidant rescue in colon cancer cells","pmids":["21156786"],"confidence":"High","gaps":["Whether ZBTB10 binds Sp gene promoters directly or acts indirectly was not established","No genome-wide target identification performed","Mechanism of ZBTB10-mediated Sp repression (competition vs. active repression) unclear"]},{"year":2012,"claim":"Cross-cancer validation in breast and ovarian models confirmed the miR-27a/ZBTB10/Sp axis as a general oncogenic circuit rather than a colon cancer-specific phenomenon.","evidence":"ZBTB10 overexpression and miR-27a inhibition in breast and ovarian cancer lines; in vivo xenograft validation","pmids":["22407812","22553354","23254909"],"confidence":"High","gaps":["Direct ZBTB10–DNA interaction at Sp promoters still not demonstrated","Physiological regulation of ZBTB10 beyond miRNA-mediated suppression unknown"]},{"year":2019,"claim":"Discovery that ZBTB10 binds variant TTGGGG telomeric repeats and interacts with TRF2/RAP1 revealed an unexpected telomere biology function distinct from its Sp-repressor role.","evidence":"Quantitative DNA-binding assays, Co-IP, mass spectrometry, and fluorescence co-localization with telomeres in ALT-positive U2OS cells","pmids":["30629181"],"confidence":"High","gaps":["Functional consequence of ZBTB10 loss at ALT telomeres not tested","Whether telomere binding and Sp repression are independent or coordinated is unknown","Role in telomere maintenance or recombination not addressed"]},{"year":2021,"claim":"Showing that ZBTB10 is required for NF-κB activation in dendritic cells—by repressing NKRF—extended its functional repertoire to innate immune regulation.","evidence":"shRNA knockdown in Mutu-DC cDC1 line with transcriptome analysis, p65/RelB nuclear translocation assays, and T cell co-culture","pmids":["33527393"],"confidence":"Medium","gaps":["Whether ZBTB10 directly binds the NKRF promoter was not tested","In vivo immune phenotype of ZBTB10 deficiency not established","Findings from a single immortalized DC line"]},{"year":2022,"claim":"Identification of PKLR as a direct transcriptional target of ZBTB10 linked its loss to metabolic reprogramming and neuroendocrine differentiation in therapy-resistant prostate cancer.","evidence":"Loss-of-function studies and direct transcriptional regulation assays in prostate cancer cell lines","pmids":["35306527"],"confidence":"Medium","gaps":["ChIP-based confirmation of direct promoter binding not explicitly shown","Mechanism coupling ZBTB10 loss to androgen-deprivation resistance not defined"]},{"year":2023,"claim":"Solving the crystal structure of ZBTB10 ZF1-2 bound to TTGGGG DNA provided the atomic basis for variant repeat selectivity and showed a single residue switch (Arg767Gln) redirects binding to canonical TTAGGG.","evidence":"X-ray crystallography, ITC, and site-directed mutagenesis with co-crystal of mutant–TTAGGG complex","pmids":["36657642"],"confidence":"High","gaps":["Full-length structural information including the BTB domain is lacking","Whether the Arg767Gln variant exists naturally is unknown","How zinc finger binding integrates with BTB domain-mediated protein interactions not resolved"]},{"year":2023,"claim":"Demonstrating that ZBTB10 directly binds and activates the HK1 promoter established it as a context-dependent transcriptional activator, not solely a repressor.","evidence":"ChIP and luciferase reporter assays in laryngeal cancer and 293T cells with knockdown/overexpression","pmids":["37834257"],"confidence":"Medium","gaps":["What determines whether ZBTB10 activates versus represses a given promoter is unknown","Co-factor requirements for activation not identified"]},{"year":2025,"claim":"Identifying the ZBTB10→ARRDC3→ITGB4 ubiquitination axis that suppresses PI3K/AKT signaling defined a complete tumor-suppressive signaling chain from transcription factor to phospho-proteome.","evidence":"ChIP, Co-IP, luciferase reporter, RNA-seq, phosphoproteomics, and xenograft models in gastric cancer","pmids":["39873948"],"confidence":"High","gaps":["Whether this axis operates in non-cancer tissues is untested","Upstream signals controlling ZBTB10 expression beyond miRNAs remain poorly characterized"]},{"year":null,"claim":"It remains unknown how ZBTB10's dual roles—Sp/promoter-level transcription regulation and variant telomeric repeat binding—are coordinated, what determines its activator versus repressor function at different promoters, and what its physiological role is in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["No in vivo knockout/conditional model phenotype reported","Genome-wide binding profile (ChIP-seq) not published","Functional consequence of telomeric binding on ALT mechanisms not tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[4,8,9,10]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,6,9,10]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,5]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[4,8]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,6,9,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,10]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5]}],"complexes":[],"partners":["TRF2","RAP1","SP1","SP3","SP4","ARRDC3"],"other_free_text":[]},"mechanistic_narrative":"ZBTB10 is a BTB/POZ-zinc finger transcription factor that functions as a transcriptional repressor and activator, with additional roles in telomere biology and immune signaling. ZBTB10 represses Sp1, Sp3, and Sp4 transcription factors, thereby downregulating Sp-dependent target genes including cyclin D1, VEGF, survivin, and MDR1; its own expression is post-transcriptionally suppressed by miR-27a and miR-361-5p [PMID:21156786, PMID:35608340]. Its two C2H2 zinc fingers bind variant telomeric TTGGGG repeats with nanomolar affinity—structurally resolved by crystallography—and its N-terminal region interacts with TRF2/RAP1, localizing ZBTB10 to ALT telomeres [PMID:30629181, PMID:36657642]. ZBTB10 also directly binds and regulates the promoters of metabolic genes (HK1 activation, PKLR repression, ARRDC3 activation), modulating glycolysis and PI3K/AKT signaling in cancer contexts, and is required for NF-κB activation in conventional dendritic cells through repression of NKRF [PMID:37834257, PMID:35306527, PMID:39873948, PMID:33527393]."},"prefetch_data":{"uniprot":{"accession":"Q96DT7","full_name":"Zinc finger and BTB domain-containing protein 10","aliases":["Zinc finger protein RIN ZF"],"length_aa":871,"mass_kda":94.9,"function":"May be involved in transcriptional regulation","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q96DT7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZBTB10","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"IPO8","stoichiometry":10.0},{"gene":"CSNK2B","stoichiometry":0.2},{"gene":"MIF","stoichiometry":0.2},{"gene":"SRP9","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ZBTB10","total_profiled":1310},"omim":[{"mim_id":"618576","title":"ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 10; ZBTB10","url":"https://www.omim.org/entry/618576"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZBTB10"},"hgnc":{"alias_symbol":["RINZF","FLJ12752"],"prev_symbol":[]},"alphafold":{"accession":"Q96DT7","domains":[{"cath_id":"3.30.710.10","chopping":"344-397_404-481","consensus_level":"medium","plddt":79.2725,"start":344,"end":481},{"cath_id":"3.30.160.60","chopping":"726-776","consensus_level":"medium","plddt":79.4941,"start":726,"end":776},{"cath_id":"-","chopping":"777-811","consensus_level":"medium","plddt":70.5049,"start":777,"end":811}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96DT7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96DT7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96DT7-F1-predicted_aligned_error_v6.png","plddt_mean":48.91},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZBTB10","jax_strain_url":"https://www.jax.org/strain/search?query=ZBTB10"},"sequence":{"accession":"Q96DT7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96DT7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96DT7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96DT7"}},"corpus_meta":[{"pmid":"21156786","id":"PMC_21156786","title":"GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway.","date":"2010","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/21156786","citation_count":95,"is_preprint":false},{"pmid":"22407812","id":"PMC_22407812","title":"Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10.","date":"2012","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22407812","citation_count":84,"is_preprint":false},{"pmid":"22553354","id":"PMC_22553354","title":"Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer.","date":"2012","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22553354","citation_count":74,"is_preprint":false},{"pmid":"23471840","id":"PMC_23471840","title":"The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis.","date":"2013","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/23471840","citation_count":65,"is_preprint":false},{"pmid":"26562150","id":"PMC_26562150","title":"Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations.","date":"2015","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/26562150","citation_count":51,"is_preprint":false},{"pmid":"30629181","id":"PMC_30629181","title":"ZBTB10 binds the telomeric variant repeat TTGGGG and interacts with TRF2.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30629181","citation_count":30,"is_preprint":false},{"pmid":"23254909","id":"PMC_23254909","title":"The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23254909","citation_count":30,"is_preprint":false},{"pmid":"35306527","id":"PMC_35306527","title":"Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35306527","citation_count":15,"is_preprint":false},{"pmid":"33527393","id":"PMC_33527393","title":"Zbtb10 transcription factor is crucial for murine cDC1 activation and cytokine secretion.","date":"2021","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33527393","citation_count":13,"is_preprint":false},{"pmid":"36657642","id":"PMC_36657642","title":"Structural insights into the recognition of telomeric variant repeat TTGGGG by broad-complex, tramtrack and bric-à-brac - zinc finger protein ZBTB10.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36657642","citation_count":9,"is_preprint":false},{"pmid":"37834257","id":"PMC_37834257","title":"Intermittent Hypoxia Promotes TAM-Induced Glycolysis in Laryngeal Cancer Cells via Regulation of HK1 Expression through Activation of ZBTB10.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37834257","citation_count":9,"is_preprint":false},{"pmid":"35608340","id":"PMC_35608340","title":"MiR-361-5p promotes proliferation and inhibits apoptosis of fibroblast-like synoviocytes via targeting ZBTB10 in rheumatoid arthritis.","date":"2022","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/35608340","citation_count":8,"is_preprint":false},{"pmid":"39873948","id":"PMC_39873948","title":"Enhanced ZBTB10 expression induced by betulinic acid inhibits gastric cancer progression by inactivating the ARRDC3/ITGB4/PI3K/AKT pathway.","date":"2025","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/39873948","citation_count":4,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8184,"output_tokens":2835,"usd":0.033538},"stage2":{"model":"claude-opus-4-6","input_tokens":6176,"output_tokens":2351,"usd":0.134483},"total_usd":0.168021,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"ZBTB10 functions as a transcriptional repressor of specificity protein (Sp) transcription factors Sp1, Sp3, and Sp4; its expression is suppressed by miR-27a, and induction of ROS downregulates miR-27a, thereby inducing ZBTB10 and repressing Sp-regulated genes (cyclin D1, c-Met, EGFR, bcl-2, survivin, VEGF/VEGFRs) in colon cancer cells.\",\n      \"method\": \"RNA interference, expression plasmid transfection, miR-27a modulation, RT-PCR, Western blot in RKO and SW480 colon cancer cells\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (RNAi, overexpression, antioxidant rescue), replicated across multiple papers\",\n      \"pmids\": [\"21156786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Overexpression of ZBTB10 recapitulates Sp1/Sp3/Sp4 downregulation and reduces VEGF, survivin, and other Sp-regulated gene expression in breast cancer cells, confirming its role as an Sp repressor; miR-27a constitutively suppresses ZBTB10 expression, and betulinic acid disrupts this axis via cannabinoid receptor CB1/CB2-dependent signaling.\",\n      \"method\": \"ZBTB10 expression plasmid transfection, miR-27a mimic/inhibitor transfection, siRNA knockdown, Western blot, RT-PCR in MDA-MB-231 and BT474/MDA-MB-453 cells; xenograft mouse model\",\n      \"journal\": \"Molecular carcinogenesis; Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods across two independent studies, including in vivo validation\",\n      \"pmids\": [\"22407812\", \"22553354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-27a directly suppresses ZBTB10 expression; downregulation of miR-27a by follicle stimulating hormone leads to decreased ZBTB10, increased Sp1 activity, and upregulation of VEGF, Cox2, and survivin in ovarian cancer cells; antisense miR-27a or ZBTB10 overexpression blocks this FSH-induced response.\",\n      \"method\": \"Antisense miR-27a transfection, ZBTB10 overexpression, Sp1 siRNA knockdown, Western blot, RT-PCR in ovarian cancer cells\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods but single laboratory study\",\n      \"pmids\": [\"23254909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ROS-mediated disruption of the miR-27a:ZBTB10 axis by curcuminoids induces ZBTB10, represses Sp1/Sp3/Sp4, and downregulates MDR1, demonstrating that Sp1/Sp3 regulate MDR1 expression downstream of ZBTB10 in colon cancer cells.\",\n      \"method\": \"RT-PCR, transfection with ZBTB10 expression construct and RNAi, Western blot in SW-480 and HT-29 colon cancer cells\",\n      \"journal\": \"Molecular nutrition & food research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods but single laboratory\",\n      \"pmids\": [\"23471840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZBTB10 is the first identified TTGGGG variant telomeric repeat-binding protein; its two C2H2 zinc fingers bind TTGGGG with nanomolar affinity, and its N-terminal region interacts with TRF2/RAP1; ZBTB10 co-localizes with a subset of telomeres in ALT-positive U2OS cells.\",\n      \"method\": \"DNA binding assays, pull-down, co-immunoprecipitation, fluorescence microscopy (co-localization), quantitative mass spectrometry\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding assay with affinity measurement, protein interaction by Co-IP, and localization by imaging, orthogonal methods in one study\",\n      \"pmids\": [\"30629181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZBTB10 is required for NF-κB activation in conventional dendritic cells (cDC1); ZBTB10 knockdown increases NKRF (NF-κB repressing factor) expression, abrogates p65 and RelB nuclear translocation, and suppresses co-stimulatory molecules (CD80, CD86) and cytokines (IL-12, IL-6, IL-10), impairing Th1 T cell differentiation.\",\n      \"method\": \"Zbtb10 shRNA knockdown in Mutu-DC cDC1 line, global transcriptome analysis, Western blot for p65/RelB nuclear translocation, T cell co-culture assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with specific cellular and molecular phenotypic readouts, transcriptome validation, single laboratory\",\n      \"pmids\": [\"33527393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZBTB10 directly transcriptionally represses PKLR (pyruvate kinase L/R); loss of ZBTB10 in androgen-deprivation therapy-resistant prostate cancer activates PKLR, enhancing glycolysis and neuroendocrine differentiation.\",\n      \"method\": \"Loss-of-function studies, gene expression analysis, direct transcriptional regulation assays in prostate cancer cell lines\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct transcriptional regulation demonstrated with loss-of-function, single laboratory\",\n      \"pmids\": [\"35306527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZBTB10 is a direct target of miR-361-5p; overexpression of ZBTB10 reverses the pro-proliferative and anti-apoptotic effects of miR-361-5p in rheumatoid arthritis fibroblast-like synoviocytes, establishing a miR-361-5p/ZBTB10 regulatory axis in these cells.\",\n      \"method\": \"Dual luciferase reporter assay, rescue/overexpression experiments, CCK-8, flow cytometry, Western blot in RA-FLS cells\",\n      \"journal\": \"Autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct target validation by luciferase assay plus rescue experiments, single laboratory\",\n      \"pmids\": [\"35608340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Crystal structure of human ZBTB10 ZF1-2 in complex with double-stranded TTGGGG DNA revealed the molecular basis of variant telomeric repeat recognition; key residues were identified by calorimetric analysis and mutagenesis; a single amino acid mutant (Arg767Gln) shifts specificity toward TTAGGG.\",\n      \"method\": \"X-ray crystallography, isothermal titration calorimetry, site-directed mutagenesis, co-crystal structure of mutant with TTAGGG\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with calorimetric validation and mutagenesis in a single rigorous study\",\n      \"pmids\": [\"36657642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZBTB10 directly binds the HK1 promoter and activates HK1 transcription; in intermittent hypoxia, ZBTB10 is upregulated and drives HK1-dependent glycolysis in laryngeal cancer cells.\",\n      \"method\": \"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), ZBTB10 knockdown and overexpression, HK1 shRNA in laryngeal cancer and 293T cells\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and luciferase assays provide direct evidence of promoter binding and transcriptional activation, single laboratory\",\n      \"pmids\": [\"37834257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZBTB10 directly binds the ARRDC3 promoter to enhance ARRDC3 expression; elevated ARRDC3 interacts with β-4 integrin (ITGB4) and promotes its ubiquitination and degradation, leading to reduced PI3K/AKT phosphorylation and suppression of gastric cancer progression.\",\n      \"method\": \"Chromatin immunoprecipitation, co-immunoprecipitation, luciferase reporter assay, RNA-sequencing, phospho-proteomic profiling, ZBTB10 overexpression in vitro and xenograft models\",\n      \"journal\": \"Cellular oncology (Dordrecht, Netherlands)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP for direct promoter binding, Co-IP for ARRDC3-ITGB4 interaction, phosphoproteomics, and in vivo validation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"39873948\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZBTB10 is a BTB-ZF transcription factor that acts as a repressor of Sp1/Sp3/Sp4 transcription factors (itself suppressed post-transcriptionally by miR-27a and miR-361-5p), directly binds variant telomeric TTGGGG repeats via its C2H2 zinc fingers and interacts with TRF2/RAP1 at ALT telomeres, transcriptionally activates or represses target genes (including ARRDC3, HK1, and PKLR) through direct promoter binding, and modulates NF-κB signaling in dendritic cells, collectively regulating cancer cell proliferation, metabolism, and immune activation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ZBTB10 is a BTB/POZ-zinc finger transcription factor that functions as a transcriptional repressor and activator, with additional roles in telomere biology and immune signaling. ZBTB10 represses Sp1, Sp3, and Sp4 transcription factors, thereby downregulating Sp-dependent target genes including cyclin D1, VEGF, survivin, and MDR1; its own expression is post-transcriptionally suppressed by miR-27a and miR-361-5p [PMID:21156786, PMID:35608340]. Its two C2H2 zinc fingers bind variant telomeric TTGGGG repeats with nanomolar affinity—structurally resolved by crystallography—and its N-terminal region interacts with TRF2/RAP1, localizing ZBTB10 to ALT telomeres [PMID:30629181, PMID:36657642]. ZBTB10 also directly binds and regulates the promoters of metabolic genes (HK1 activation, PKLR repression, ARRDC3 activation), modulating glycolysis and PI3K/AKT signaling in cancer contexts, and is required for NF-κB activation in conventional dendritic cells through repression of NKRF [PMID:37834257, PMID:35306527, PMID:39873948, PMID:33527393].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Establishing ZBTB10 as the missing Sp transcription factor repressor resolved how ROS and miR-27a converge to control Sp-dependent oncogene programs.\",\n      \"evidence\": \"miR-27a modulation, ZBTB10 overexpression/RNAi, and antioxidant rescue in colon cancer cells\",\n      \"pmids\": [\"21156786\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether ZBTB10 binds Sp gene promoters directly or acts indirectly was not established\",\n        \"No genome-wide target identification performed\",\n        \"Mechanism of ZBTB10-mediated Sp repression (competition vs. active repression) unclear\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Cross-cancer validation in breast and ovarian models confirmed the miR-27a/ZBTB10/Sp axis as a general oncogenic circuit rather than a colon cancer-specific phenomenon.\",\n      \"evidence\": \"ZBTB10 overexpression and miR-27a inhibition in breast and ovarian cancer lines; in vivo xenograft validation\",\n      \"pmids\": [\"22407812\", \"22553354\", \"23254909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct ZBTB10–DNA interaction at Sp promoters still not demonstrated\",\n        \"Physiological regulation of ZBTB10 beyond miRNA-mediated suppression unknown\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery that ZBTB10 binds variant TTGGGG telomeric repeats and interacts with TRF2/RAP1 revealed an unexpected telomere biology function distinct from its Sp-repressor role.\",\n      \"evidence\": \"Quantitative DNA-binding assays, Co-IP, mass spectrometry, and fluorescence co-localization with telomeres in ALT-positive U2OS cells\",\n      \"pmids\": [\"30629181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional consequence of ZBTB10 loss at ALT telomeres not tested\",\n        \"Whether telomere binding and Sp repression are independent or coordinated is unknown\",\n        \"Role in telomere maintenance or recombination not addressed\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that ZBTB10 is required for NF-κB activation in dendritic cells—by repressing NKRF—extended its functional repertoire to innate immune regulation.\",\n      \"evidence\": \"shRNA knockdown in Mutu-DC cDC1 line with transcriptome analysis, p65/RelB nuclear translocation assays, and T cell co-culture\",\n      \"pmids\": [\"33527393\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether ZBTB10 directly binds the NKRF promoter was not tested\",\n        \"In vivo immune phenotype of ZBTB10 deficiency not established\",\n        \"Findings from a single immortalized DC line\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of PKLR as a direct transcriptional target of ZBTB10 linked its loss to metabolic reprogramming and neuroendocrine differentiation in therapy-resistant prostate cancer.\",\n      \"evidence\": \"Loss-of-function studies and direct transcriptional regulation assays in prostate cancer cell lines\",\n      \"pmids\": [\"35306527\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"ChIP-based confirmation of direct promoter binding not explicitly shown\",\n        \"Mechanism coupling ZBTB10 loss to androgen-deprivation resistance not defined\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Solving the crystal structure of ZBTB10 ZF1-2 bound to TTGGGG DNA provided the atomic basis for variant repeat selectivity and showed a single residue switch (Arg767Gln) redirects binding to canonical TTAGGG.\",\n      \"evidence\": \"X-ray crystallography, ITC, and site-directed mutagenesis with co-crystal of mutant–TTAGGG complex\",\n      \"pmids\": [\"36657642\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Full-length structural information including the BTB domain is lacking\",\n        \"Whether the Arg767Gln variant exists naturally is unknown\",\n        \"How zinc finger binding integrates with BTB domain-mediated protein interactions not resolved\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that ZBTB10 directly binds and activates the HK1 promoter established it as a context-dependent transcriptional activator, not solely a repressor.\",\n      \"evidence\": \"ChIP and luciferase reporter assays in laryngeal cancer and 293T cells with knockdown/overexpression\",\n      \"pmids\": [\"37834257\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"What determines whether ZBTB10 activates versus represses a given promoter is unknown\",\n        \"Co-factor requirements for activation not identified\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying the ZBTB10→ARRDC3→ITGB4 ubiquitination axis that suppresses PI3K/AKT signaling defined a complete tumor-suppressive signaling chain from transcription factor to phospho-proteome.\",\n      \"evidence\": \"ChIP, Co-IP, luciferase reporter, RNA-seq, phosphoproteomics, and xenograft models in gastric cancer\",\n      \"pmids\": [\"39873948\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether this axis operates in non-cancer tissues is untested\",\n        \"Upstream signals controlling ZBTB10 expression beyond miRNAs remain poorly characterized\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how ZBTB10's dual roles—Sp/promoter-level transcription regulation and variant telomeric repeat binding—are coordinated, what determines its activator versus repressor function at different promoters, and what its physiological role is in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No in vivo knockout/conditional model phenotype reported\",\n        \"Genome-wide binding profile (ChIP-seq) not published\",\n        \"Functional consequence of telomeric binding on ALT mechanisms not tested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4, 8, 9, 10]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 6, 9, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [4, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 6, 9, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TRF2\",\n      \"RAP1\",\n      \"SP1\",\n      \"SP3\",\n      \"SP4\",\n      \"ARRDC3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}